Clinical application of hypoxia inducible factor proline hydroxylase inhibitor in restless legs syndrome of end stage renal disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039194

Enrollment

Unknown

Registered

2020-10-21

Start date

2020-10-30

Completion date

Unknown

Last updated

2021-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

restless legs syndrome

Interventions

HIF-PHI:Roxadustat

Oral neurotropin:Oral neurotropin

Intravenous injection of neurotropin:Neurotropin injection

HDF:HDF

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: The patients with MHD were older than 18 years old and less than 70 years old, who received regular hemodialysis treatment for more than 6 months, 3 times a week, and more than 12 hours a week.

Exclusion criteria

Exclusion criteria: Patients with mental disorders; those who are taking dopamine, anticonvulsant, benzodiazepines or opioids to control restless legs symptoms; patients with peripheral neuropathy.

Design outcomes

Primary

Measure	Time frame
routine blood test;Serum electrolytes;Serum liver and kidney function;Detection of serum iron;Serum ferritin;Serum calcium, phosphorus and magnesium;Serum C-reactive protein;Serum parathyroid hormone;Serum 25 hydroxyvitamin D;Restless legs syndrome research evaluation scale;	—

Countries

China

Contacts

Public ContactHaibo Yu

The Sencond Hospital of Tianjin Medical University

yuhaibo2001@126.com+86 13512284415

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026